Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Xintela AB
XINTXintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM that is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indications; and EQSTEM, which is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies, such as TARG9 and TARG10, which are in preclinical study for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. It has an agreement with Region Östergötland for GMP process development of cell therapy for burn patients. Xintela AB (publ) was incorporated in 2009 and is based in Lund, Sweden. Address: Medicon Village, Lund, Sweden, 223 81
Analytics
Preço Alvo de Wall Street
–Rácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave XINT
Análise de Dividendos XINT
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos XINT
Avaliação de ações XINT
Relatório XINT
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |